Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia [Research Articles]

This article is highlighted in the In This Issue feature, p. 443

Source: Cancer Discovery - April 30, 2017 Category: Cancer & Oncology Authors: Shih, A. H., Meydan, C., Shank, K., Garrett-Bakelman, F. E., Ward, P. S., Intlekofer, A. M., Nazir, A., Stein, E. M., Knapp, K., Glass, J., Travins, J., Straley, K., Gliser, C., Mason, C. E., Yen, K., Thompson, C. B., Melnick, A., Levine, R. L. Tags: Research Articles Source Type: research